Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis
Pooled result · CHD death, MI, ischemic stroke or coronary revascularizationResult — go to the resultHazard ratio 0.77 95% CI 0.54–1.11Authors' conclusion
Obicetrapib treatment associated with a reduction in coronary events, evident beyond 6 months of treatment.
Study context
- Population
- Patients with heterozygous familial hypercholesterolemia (HeFH) (354) or atherosclerotic cardiovascular disease (ASCVD) (2,530)354 HeFH + 2,530 ASCVD
- Comparison
- Obicetrapib 10 mg daily vs placebo
- Outcome
- Major adverse cardiovascular event (MACE):
- CHD death
- MI
- Ischemic stroke
- Coronary revascularization
- Follow-up
- 365 days
Pooled result
As reported in the abstract
CHD death, MI, ischemic stroke or coronary revascularization
Hazard ratio
0.77
95% CI 0.54–1.11
P = 0.16
By group
Obicetrapibvs Placebo
HR 0.77 (95% CI 0.54–1.11); P = 0.16
Further pooled results
| Outcome | Obicetrapib | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| CHD death, MI, ischemic stroke or coronary revascularization, second 6 months | 0.60 (0.37–0.99) | P = 0.04 | |||
| CHD death, MI or coronary revascularization | 3.2% | 4.7% | 0.68 (0.46–1.00) | P = 0.048 | |
| CHD death, MI or coronary revascularization, second 6 months | 0.45 (0.26–0.77) | P = 0.003 | |||
| 0.20.5125Hazard ratio (log scale) |
| Outcome | Obicetrapib | Placebo |
|---|---|---|
| Lipid changes | ||
| LDL-C | −34.0 mg/dL, −37.8% | −4.0 mg/dL, −4.6% |
| ApoB | −19.0 mg/dL, −21.7% | −3.0 mg/dL, −3.6% |
| non-HDL-C | −36.0 mg/dL, −32.4% | −4.0 mg/dL, −3.7% |
| Lp(a) | −9.8 nmol/L, −32.5% | 0 nmol/L, 0% |
| HDL-C | +68.0 mg/dL, +140.0% | +1.0 mg/dL, +1.5% |
Achieved lipid levels and event rates
- LDL-C associated with event rates
- P = 0.003
- Apolipoprotein B (ApoB) associated with event rates
- P = 0.007
- non-HDL-C associated with event rates
- P = 0.01
- Lp(a) associated with event rates
- P = 0.003
- High-density lipoprotein cholesterol (HDL-C) associated with event rates
- P = 0.0001
Original publication
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. Published 1 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →